Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Rule 8.3 - Celsis International plc

26 Aug 2009 14:26

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers)

1. KEY INFORMATION

Name of person dealing (Note 1) Gartmore Investment Management Ltd Company dealt in Celsis International plc Class of relevant security to Ord GBP 0.005

which the dealings being disclosed relate (Note 2) Date of dealing 25th August 2009

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) Interests and short positions (following dealing) in the class of relevantsecurity dealt in (Note 3) Long Short Number (%) Number (%) (1) Relevant securities 1,088,384 (4.97%) (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total 1,088,384 (4.97%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short Number (%) Number (%) (1) Relevant securities (2) Derivatives (other than options)

(3) Options and agreements to purchase/sell Total

(c) Rights to subscribe (Note 3)

Class of relevant security: Details 3. DEALINGS (Note 4)(a) Purchases and salesPurchase/sale Number of securities Price per unit (Note 5) Sale 187,629 GBP2.325

(b) Derivatives transactions (other than options)

Product name, Long/short (Note Number of securities Price per unit (Note 6) (Note 7) 5) e.g. CFD

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name, Writing, Number of Exercise Type, e.g. Expiry Option

selling, securities to American, money e.g. call purchasing, which the price European Date option varying option etc. paid/ etc. relates (Note received 7) per unit (Note 5) (ii) ExercisingProduct name, e.g. call Number of securities Exercise price per unit option (Note 5)

(d) Other dealings (including new securities) (Note 4)

Nature of transaction Details Price per unit (if (Note 8) applicable) (Note 5) 4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure 26th August 2009 Contact name Alison Averono Telephone number 0207 782 2324

If a connected EFM, name of offeree/offeror N/A with which connected If a connected EFM, state nature of N/A connection (Note 10)

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

vendor
Date   Source Headline
8th Aug 20257:00 amRNSCancellation - Celadon Pharmaceuticals Plc
5th Aug 20256:00 pmRNSCeladon Pharmaceuticals
28th Jul 20254:10 pmRNSResult of General Meeting
2nd Jul 20257:00 amRNSProposed Cancellation
1st Jul 202511:48 amRNSFunding Update
1st Jul 20258:20 amRNSResult of AGM
1st Jul 20257:30 amRNSSuspension - Celadon Pharmaceuticals Plc
30th Jun 20257:00 amRNSFunding and Operational Update, Delay in Results
11th Jun 20257:00 amRNSNew Committed Credit Facility
6th Jun 20253:55 pmRNSFunding Update, Notice of AGM
30th May 20256:07 pmRNSFunding Update
30th Apr 20257:00 amRNSFunding Update
8th Apr 20253:05 pmRNSTermination of Facility
31st Mar 20253:15 pmRNSFunding Update
24th Mar 20257:00 amRNSBoard Changes and De-Listing Proposal
19th Mar 20257:00 amRNSFunding Update
26th Feb 20251:00 pmRNSNew Committed Credit Facility
12th Feb 20257:00 amRNSFinance Update
31st Jan 20257:00 amRNSFinance Update
16th Jan 20257:00 amRNSUpdate on Strategic Collaboration
2nd Jan 20257:00 amRNSFunding Update
20th Dec 20247:00 amRNSFinance Update
6th Dec 20247:00 amRNSReceipt of Subscription Proceeds
18th Nov 20247:00 amRNSUpdate on Financial Position
2nd Oct 20247:00 amRNSNew Sales Contract with a Healthcare Company
30th Sep 20247:05 amRNSDeparture of Chief Financial Officer
30th Sep 20247:00 amRNSInterim Results
17th Sep 20249:28 amRNSAdmission of Shares and Total Voting Rights
11th Sep 20247:05 amRNSEquity Fundraise and Update on Financial Position
11th Sep 20247:00 amRNSStrategic collaboration with Valeos
23rd Aug 20247:00 amRNSUpdate on Financial Position
12th Aug 20247:00 amRNSUpdate on Operations and Financial Position
16th Jul 20247:00 amRNSSuccessful Completion of Eighth Harvest of 2024
15th Jul 20241:58 pmRNSThird Admission of Shares
28th Jun 20247:00 amRNSResult of AGM
7th Jun 20247:00 amRNSSecond Admission of Shares
3rd Jun 20245:45 pmRNSPublication of Annual Report & Notice of AGM
23rd May 20247:00 amRNSSupply of Products to New US Customer
15th May 20242:45 pmRNSExercise of Share Options and Total Voting Rights
14th May 20247:00 amRNSFinal Results
10th May 20247:00 amRNSFundraise, RCF Extension, Termination of CLN & TVR
7th Mar 20247:00 amRNSEarly Economic Analysis of Feasibility Study Data
14th Dec 20237:00 amRNSProduct Supplied to First Two Sales Contracts
12th Dec 20232:00 pmRNSFundraise, Update on Future CLN Financing & TVR
16th Nov 20237:00 amRNSNew European Sales Contract
13th Oct 20237:00 amRNSFundraise, CLN Issue, Joint Broker Appointed & TVR
28th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSNotice of Results and Investor Presentation
5th Sep 20237:00 amRNSNew Sales Contract with UK Pharmaceutical Company
1st Aug 20237:00 amRNSApproval to roll-out chronic pain clinical trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.